Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | F10 | P00742 | 9/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6377501 | 0.95 | USP30 (0.60) | USP30HDAC4HDAC6F10GABRA5 | |
| SCHEMBL5145035 | 0.86 | USP30 (0.82) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL5428052 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL5428063 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL4691128 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL5437993 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL5437984 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL5437990 | 0.83 | F10 (0.53) | USP30F10 | |
| SCHEMBL17927199 | 0.83 | HDAC4 (0.70) | USP30HDAC4HDAC6GABRA5PARP1 | |
| SCHEMBL2467955 | 0.82 | USP30 (0.67) | USP30HDAC4HDAC6GABRA5PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | USP30 1504/4885HDAC4 1093/4885HDAC6 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.